Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» kidney disease
kidney disease
Calliditas starts Phase II trial for rare kidney disease therapy
Calliditas starts Phase II trial for rare kidney disease therapy
Clinical Trials Arena
Calliditas Therapeutics
clinical trials
Alport syndrome
kidney disease
setanaxib
Flag link:
Travere Touts Phase III Kidney Disease Data for Filspari After Trial Failures
Travere Touts Phase III Kidney Disease Data for Filspari After Trial Failures
BioSpace
Travere Therapeutics
kidney disease
Filspari
clinical trials
Flag link:
As trial miss threatens FDA approval, Travere points to Filspari's benefits in bid to stay in kidney disease
As trial miss threatens FDA approval, Travere points to Filspari's benefits in bid to stay in kidney disease
Fierce Pharma
Travere Therapeutics
Filspari
IgA nephropathy
kidney disease
FDA
Flag link:
Omeros terminates kidney disease trial as therapy fails in late-stage study
Omeros terminates kidney disease trial as therapy fails in late-stage study
Reuters
Omeros
kidney disease
clinical trials
narsoplimab
Berger's disease
Flag link:
AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million
AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million
Forbes
AstraZeneca
legal
kidney disease
heartburn
Nexium
Prilosec
Flag link:
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
Clinical Trials Arena
Novartis
clinical trials
iptacopan
IgA nephropathy
kidney disease
Flag link:
Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
BioSpace
Travere Therapeutics
kidney disease
sparsentan
Filspari
clinical trials
Flag link:
ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect
ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect
Fierce Pharma
ProKidney
drug manufacturing
North Carolina
kidney disease
Flag link:
Novartis to acquire kidney disease biotech Chinook for up to $3.5B
Novartis to acquire kidney disease biotech Chinook for up to $3.5B
BioPharma Dive
Novartis
Chinook Therapeutics
M&A
kidney disease
Flag link:
HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions
HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions
Fierce Biotech
Hi-Bio
Human Immunology Bioscience
kidney disease
felzartamab
Flag link:
Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments
Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments
Fierce Biotech
Goldfinch Bio
GFB-887
kidney disease
Flag link:
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
Endpoints
Roche
Ionis Pharmaceuticals
IONIS-FB-LRx
kidney disease
Flag link:
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
MedCity News
Human Immunology Bioscience
autoimmune disease
R&D
MorphoSys
kidney disease
Flag link:
Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug
Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug
Fierce Biotech
Tricida
clinical trial
kidney disease
Veverimer
Flag link:
FDA’s liver safety request set to delay decision on Travere’s kidney drug
FDA’s liver safety request set to delay decision on Travere’s kidney drug
Fierce Biotech
Travere Therapeutics
kidney disease
REMS
FDA
Flag link:
Regulus reports positive findings from Phase I kidney disease trial
Regulus reports positive findings from Phase I kidney disease trial
Clinical Trials Arena
Regulus
kidney disease
RGLS8429
clinical trials
Flag link:
Where Will Vertex Pharmaceuticals Be in 1 Year?
Where Will Vertex Pharmaceuticals Be in 1 Year?
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
kidney disease
Flag link:
Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment
Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment
Fierce Biotech
Novartis
Gilenya
kidney disease
chronic kidney disease
Flag link:
Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again
Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again
Endpoints
Travere Therapeutics
Martin Shkreli
sparsentan
FDA
kidney disease
Flag link:
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant
Fierce Biotech
Bayer
Ionis Pharmaceuticals
kidney disease
clinical trials
fesomersen
Flag link:
Pages
1
2
3
4
5
6
7
next ›
last »